(Q41164173)

27 September 2017

1 reference

title

The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock (English)

1 reference

27 September 2017

0 references

1 reference

M P Glauser

1

1 reference

27 September 2017

publication date

1 January 1996

1 reference

27 September 2017

1 reference

27 September 2017

volume

52 Suppl 2

1 reference

27 September 2017

page(s)

9-17

1 reference

Bactericidal/permeability-increasing protein and lipopolysaccharide (LPS)-binding protein. LPS binding properties and effects on LPS-mediated cell activation

27 September 2017

cites work

1 reference

12 December 2020

Recognition of endotoxin by cells leading to transmembrane signaling

1 reference

12 December 2020

A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides

1 reference

12 December 2020

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

1 reference

12 December 2020

Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes

1 reference

12 December 2020

Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide)

1 reference

12 December 2020

Soluble peptidoglycan-induced monokine production can be blocked by anti-CD14 monoclonal antibodies and by lipid A partial structures

1 reference

12 December 2020

A specific receptor antagonist for interleukin 1 prevents Escherichia coli ‐induced shock in rabbits

1 reference

12 December 2020

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

1 reference

12 December 2020

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group

1 reference

12 December 2020

Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes.

1 reference

12 December 2020

Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists

1 reference

12 December 2020

Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences

1 reference

12 December 2020

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group

1 reference

12 December 2020

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

1 reference

12 December 2020

In vivo protection against endotoxin by plasma high density lipoprotein

1 reference

12 December 2020

Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group

1 reference

12 December 2020

A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group

1 reference

12 December 2020

Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice.

1 reference

12 December 2020

Lipopolysaccharide-binding protein as a major plasma protein responsible for endotoxemic shock

1 reference

12 December 2020

CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein

1 reference

12 December 2020

A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice

1 reference

12 December 2020

Gram-positive organisms and sepsis

1 reference

12 December 2020

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

12 December 2020

Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-alpha production by cells in whole blood

1 reference

12 December 2020

The interleukin-1 receptor antagonist can either reduce or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats

1 reference

12 December 2020

Identifiers

1 reference